Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Exarafenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Exarafenib is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC) and melanoma. It acts by targeting proto oncogene B Raf (BRAF). It is administered through oral route.
Kinnate Biopharma overview
Kinnate Biopharma is a biotechnology company that focuses on the discovery and development of small molecule kinase inhibitor candidates for difficult-to-treat, cancers associated with genetic alterations. It is advancing the development of its lead-targeted therapy FGFR and RAF candidates. The company harnesses the proprietary, unique co-crystal structure of KIN002787 in the BRAF protein and biomarker-driven approach to drive the preclinical and clinical development of its translational research programs. Kinnate Biopharma also carries out small molecule development programs, such as Cyclin-Dependent Kinase 12 (CDK12) inhibitor. It has operations in San Francisco, the US. Kinnate Biopharma is headquartered in San Diego, California, the US.
For a complete picture of Exarafenib’s drug-specific PTSR and LoA scores, buy the report here.